Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lorlatinib

FDA-approved product (tablet, oral), marketed as Lorbrena.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lorlatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Lymphoma
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lorlatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lorlatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

    NCT02838264 · start 2016-08-16

    Registered record
    Registry ID
    NCT02838264
    Conditions
    Healthy
    Interventions
    PF-06463922; PF-06463922; PF-06463922; PF-06463922; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-08-16
    Completion
    2017-05-03
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-06463922; PF-06463922; PF-06463922; PF-06463922 +1 more
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

    NCT02584634 · start 2015-12-18

    Registered record
    Registry ID
    NCT02584634
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Avelumab; PF-06463922; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2015-12-18
    Completion
    2022-07-13
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionAvelumab; PF-06463922; Crizotinib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers

    NCT02564562 · start 2015-10

    Registered record
    Registry ID
    NCT02564562
    Conditions
    Healthy
    Interventions
    [14C] PF-06463922
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-10
    Completion
    2015-11
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Intervention[14C] PF-06463922
    PhasePhase 1
    Registry statusCompleted

  • Lorlatinib - PF-06463922

    NCT03127618

    Registered record
    Registry ID
    NCT03127618
    Conditions
    Not recorded
    Interventions
    Lorlatinib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNot recorded
    InterventionLorlatinib
    PhaseNot recorded
    Registry statusApproved for marketing

  • Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

    NCT03178071

    Registered record
    Registry ID
    NCT03178071
    Conditions
    Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
    Interventions
    Lorlatinib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer ALK Positive or ROS1 Positive
    InterventionLorlatinib
    PhaseNot recorded
    Registry statusNo longer available